Our results revealed that Prmt1 KO blocked CML development, as demonstrated by the decreased percentage of GFP+ cells in peripheral blood (PB) on days 7, 11, and 17 post‐transplantation (Figure 2C). This evidence concerns the gene PRMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.